Tradjenta (Linagliptin) Patent Expiration, LOE Window & CMS Spending

Tradjenta (Linagliptin) by Boehringer Ingelheim: FDA Orange Book LOE 2037-12-08, 8 AB generics, $1.26B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN201280 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-12-08
Orange Book Patents (*PED Extensions)16 patents (8 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$1.26B
2024 Medicare Part D Spend$1.13B
2024 Medicaid Spend$137.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.